Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Neurochem falls on Alzhemed data

Neurochem (TSX:NRM; NRMX) fell C$2.56 (44%) to C$3.30 on Monday after Alzhemed tramiprosate missed the primary

Read the full 165 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE